Alignment Healthcare, Inc. (Nasdaq: ALHC) reported second quarter 2026 results on July 30, 2026 that beat the high end of every guidance metric management had set for the period. Total revenue reached $1,335.6 million for the three months ended June 30, 2026, up 31.6% from the same quarter a year earlier, while Medicare Advantage health plan membership rose 31.5% year over year to roughly 294,100 members. The company swung to a GAAP net income of $36.6 million, up from $15.7 million in the prior-year quarter, and generated $68.1 million of adjusted EBITDA, a margin of 5.1% and a 48.4% year-over-year improvement.
The one-sentence thesis is that Alignment is a fast-growing Medicare Advantage plan whose purpose-built clinical model and proprietary AVA technology let it outgrow the industry while finally converting to sustained profit, but whose stock has been dragged down by an industry-wide deterioration in medical loss ratios and by investor anxiety over a complicated, sepsis-adjacent regulatory and accounting backdrop. The single load-bearing risk is that the Medicare Advantage sector is grinding through a cost and risk-adjustment squeeze that is compressing margins across nearly every public plan, and Alignment, despite its differentiated model, is not fully insulated from that pressure.
The falsifiable clock runs on October 29, 2026, when the company reports third quarter results and investors learn whether the medical benefits ratio held near the 86.3% level reported in the second quarter and whether full-year adjusted EBITDA lands within the raised $145 million to $163 million guidance range. Membership, which management guided to 298,000 to 301,000 for the full year, is the other leading indicator of whether this growth story remains intact.